Trastuzumab, a recombinant antibody targeting her2, was the first biological drug approved for the treatment of her2positive bc. Trastuzumab is a humanized monoclonal antibody that targets her2. Although there are currently other antiher2 agents available e. Adjuvant pertuzumab and trastuzumab in early her2positive. Antineoplasico anticuerpo monoclonal categorias farmacologicas farmacocinetica. Dual her2 targeting with trastuzumab and liposomalencapsulated doxorubicin mm 302 demonstrates synergistic antitumor activity in breast and gastric cancer. Trastuzumab was approved for medical use in the united states in 1998. Trastuzumab mechanism of action and use in clinical practice. It consists of trastuzumab, a humanized mab directed against her2, and a microtubule inhibitor, dm1, conjugated to trastuzumab.
This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Pdf dual her2 targeting with trastuzumab and liposomal. Trastuzumab mechanism of action and use in clinical practice to the editor. Herceptin indicaciones, dosificacion, presentacion, efectos. Iii study combining pertuzumab with trastuzumab and docetaxel in metastatic breast. It is on the world health organizations list of essential medicines, the safest and most effective medicines needed in a health system. Trastuzumab 440 mg20 ml en ampula oncologia info medicamento. Uncertainty over theoptimal duration of adjuvant trastuzumab therapy 5 july 20071extends to optimal sequencingandlongterm outcomes. In patients with her2positive metastatic breast cancer, pertuzumab added to trastuzumab and docetaxel has been shown to significantly prolong both progressionfree survival and overall survival. Adotrastuzumab emtansine targets hepatocytes via human. Rather than too few patients and events1, low efficacy is the likelier causeof lackingsignificant.
Ado trastuzumab emtansine tdm1 is an antibodydrug conjugate adc approved for the treatment of her2positive metastatic breast cancer. Trastuzumab works by binding to the her2 receptor and slowing down cell duplication. Pdf molecular mechanisms of trastuzumab resistance in her2. Nov 08, 2019 provides accurate and independent information on more than 24,000 prescription drugs, overthecounter medicines and natural products. The epidermal growth factor receptor 2 her2 is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. W agner ad, u nverzagt s, grothe w, kleber g, grothey a, haerting j.
1209 1235 83 20 268 943 393 224 1364 1086 592 1357 11 614 908 920 690 600 946 899 672 1455 304 435 1461 427 546 349 422